Tuesday, August 11, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Regulatory Approval Allows the Phase 2 Trial for NV-387 To Begin. NanoViricides has received approval to proceed with its Phase 2 trial of NV-387 for the treatment of Ebola in the Democratic Republic of Congo (DRC). We expect the Ebola trial to be followed by a separate Phase 2 trial in Mpox, also to be conducted in the DRC. This is consistent with our expected time frame for the trials.
Previous Preparations Should Allow Treatment To Start Soon. NanoViricides has completed delivery of clinical supplies of NV-387 oral solid formulation (gummies) for treatment of the trial. The trial will be conducted by OM Sai Clinical Research, a contract research organization (CRO) based in India. The CRO has assembled a clinical team with a Principal Investigator, local clinicians, and a university in the region to support the trial. The approval by ACOREP (Autorité Congolaise de Réglementation Pharmaceutique, the Congolese Pharmaceutical Regulatory Authority) should allow the trial to start patient treatment shortly.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.